Adivo

Germany
Martinsried, Bavaria, Germany, 82152

Company profile

Adivo company profile

adivo is a veterinary biotechnology company developing therapeutic antibodies for pets. The focus is on the treatment of serious diseases in dogs with the potential to offer therapies for other species as well. The antibody selection is based on a new, fully synthetic, dog-specific drug library that can be used to isolate antibodies with optimal properties using phage display technology. adivo is a spin-off of MorphoSys AG. Many years of expertise in the development of human therapeutic antibodies transfer the adivo team into veterinary medicine.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01

Headquarters

Postal code
82152
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Last funding
Grant / $2.8M / 2021-10-06
Last equity funding
Series Unknown
Investors
4
Lead investors
2
Founders
1
Exited on
2023-09-15

Founders and investors

Founders

Kathrin Ladetzki-Baehs

Lead investors

European Innovation CouncilOCCIDENT

Investors

European Innovation CouncilHTGF (High-Tech Gruenderfonds)MorphoSysOCCIDENT